Growing Turnover (HIV and excluding Covid) and a positive Net Accounting Result in 2023 – Testimony of ABL Diagnostics’ ability to execute and advance its major strategic projects – 01/07/2024 at 6:00 p.m.

The company ABL Diagnostics announces its accounts for the financial year ending December 31, 2023.

Highlights :

ABL Diagnostics’ net accounting result as of December 31, 2023 stands at €54,000 compared to €1,106,000 in 2022. The 2022 result was driven by an exceptional increase in activity in the context of a pandemic during which the company marketed screening kits.

In accordance with its strategy aimed at being the leader in personalized medicine in infectious diseases, ABL Diagnostics continued and strengthened its development in 2023 in its key segment, genotyping by sequencing of HIV/AIDS and co-infections.

At the same time, ABL Diagnostics continued to expand its DeepChek® product range, which mainly targets infectious, viral and bacterial applications.

Turnover:

In a post-Covid context, ABL Diagnostics achieved a turnover of €5.6 million in 2023, down €3.1 million compared to the previous financial year. The turnover adjusted for sales of COVID-19 screening kits and excluding non-recurring effects is up €215,000, an increase of 4% compared to 2022. The 2023 turnover linked to COVID is less than 1% of ABL Diagnostics’ activity.

This growth excluding exceptional and non-recurring effects is mainly driven by DeepChek® HIV products, a strategic market for ABL Diagnostics, whose number of recurring customers increased by 33% over the year 2023.